Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | F12 | P00748 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867051 | 0.87 | F12 (0.72) | MAOBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL23258437 | 0.85 | MAOB (0.56) | MAOBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL23258475 | 0.85 | MEN1 (0.69) | MAOBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL23258256 | 0.79 | MMP2 (0.57) | MAOBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2102040 | 0.79 | NPC1 (0.56) | MAOBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6239637 | 0.79 | POLB (0.58) | MAOBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL23258715 | 0.79 | MEN1 (0.57) | MAOBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL8711467 | 0.76 | ALOX5 (0.80) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14586769 | 0.76 | MMP2 (0.50) | MAOBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL13219526 | 0.76 | JAK2 (1.00) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | MAOB 108/4885KMT2A 3872/4885MEN1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.